The post Fidelity: 2026 to Be ‘Off Year’ for Bitcoin appeared on BitcoinEthereumNews.com. Jurrien Timmer, the Director of Global Macro at Fidelity Investments, The post Fidelity: 2026 to Be ‘Off Year’ for Bitcoin appeared on BitcoinEthereumNews.com. Jurrien Timmer, the Director of Global Macro at Fidelity Investments,

Fidelity: 2026 to Be ‘Off Year’ for Bitcoin

Jurrien Timmer, the Director of Global Macro at Fidelity Investments, has predicted that 2026 will be an off-year for Bitcoin, the leading cryptocurrency by market cap. 

The leading cryptocurrency is currently changing hands at $86,207, struggling to reclaim the $90,000. 

“Gold mooned while Bitcoin swooned”

As reported by U.Today, Timmer previously predicted that Bitcoin would be able to outperform gold in the second part of the year. 

However, this never happened: the yellow metal mooned while its digital rival swooned during the aforementioned time period. 

card

Timmer believes that a mean reversion is not in the cards just yet, which essentially means that he expects this trend to continue in the near future.

Has Bitcoin peaked? 

Timme believes the $125,000 price point, which Bitcoin hit two months ago in October 2025, was likely the absolute peak of this current cycle.

He argues that hitting $125k after “145 months of rallying” aligns perfectly with historical data. To him, the math shows the bull run is officially over.

He believes Bitcoin will drop from its highs to potentially find “support” between $65,000 and $75,000.

Timmer still likes Bitcoin and is bullish long-term, just not for 2026.

Other crypto predictions

Unlike Fidelity’s Timmer, Bitwise is explicitly betting against a 2026 Crypto Winter. In their “Year Ahead” report released this week, they argue that ETFs and institutional adoption have broken the old boom-and-bust patterns. The firm is confident that BTC will be able to reach a new record high next year. 

Standard Chartered and Bernstein remained bullish but have significantly lowered their expectations following the October 2025 market peak

In the meantime, as reported by U.Today, investment firm VanEck has refrained from making predictions for 2026. 

Source: https://u.today/fidelity-2026-to-be-off-year-for-bitcoin

Market Opportunity
Capverse Logo
Capverse Price(CAP)
$0.12877
$0.12877$0.12877
-0.03%
USD
Capverse (CAP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26